Compugen Ltd
NASDAQ:CGEN

Watchlist Manager
Compugen Ltd Logo
Compugen Ltd
NASDAQ:CGEN
Watchlist
Price: 1.41 USD -2.76% Market Closed
Market Cap: 126.3m USD
Have any thoughts about
Compugen Ltd?
Write Note

Compugen Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Compugen Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Compugen Ltd
NASDAQ:CGEN
Capital Expenditures
-$149k
CAGR 3-Years
12%
CAGR 5-Years
-20%
CAGR 10-Years
18%
Q
Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Biolight Life Sciences Ltd
TASE:BOLT
Capital Expenditures
-â‚Ş17k
CAGR 3-Years
80%
CAGR 5-Years
24%
CAGR 10-Years
31%
No Stocks Found

Compugen Ltd
Glance View

Market Cap
126.2m USD
Industry
Life Sciences Tools & Services

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

CGEN Intrinsic Value
1 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Compugen Ltd's Capital Expenditures?
Capital Expenditures
-149k USD

Based on the financial report for Sep 30, 2024, Compugen Ltd's Capital Expenditures amounts to -149k USD.

What is Compugen Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
18%

Over the last year, the Capital Expenditures growth was 49%. The average annual Capital Expenditures growth rates for Compugen Ltd have been 12% over the past three years , -20% over the past five years , and 18% over the past ten years .

Back to Top